P. Chong

发表

Statin‐Associated Peripheral Neuropathy: Review of the Literature

R. Bartt, P. Chong, Alexandra Boskovich, 2004, Pharmacotherapy.

Therapeutic Controversies; Lack of Therapeutic Interchangeability of HMG-CoA Reductase Inhibitors

P. Chong, 2002 .

Treatment of Atrial Fibrillation and Flutter: Focus on Oral Dofetilide, a New Selective Class III Antiarrhythmic Agent

P. Chong, C. Franklin, B. Yim, 2001, Heart Drug.

Atorvastatin Calcium: An Addition to HMG‐CoA Reductase Inhibitors

J. Seeger, P. Chong, 1997, Pharmacotherapy.

Periodontal Disease and Atherosclerotic Cardiovascular Disease: Confounding Effects or Epiphenomenon?

P. Chong, B. Kezele, Bob Kezele, 2000, Pharmacotherapy.

Diabetes Transitional Care from Inpatient to Outpatient Setting

L. Fogelfeld, P. Chong, M. Shah, 2013, Journal of pharmacy practice.

Clinically relevant differences between the statins: implications for therapeutic selection.

J. Seeger, P. Chong, C. Franklin, 2001, The American journal of medicine.

Rasburicase for the Treatment and Prevention of Hyperuricemia

P. Chong, B. Yim, R. Sims-McCallum, 2003, The Annals of pharmacotherapy.

Rosuvastatin for the Treatment of Patients with Hypercholesterolemia

P. Chong, B. Yim, 2002, The Annals of pharmacotherapy.

Niacin-ER and Lovastatin Treatment of Hypercholesterolemia and Mixed Dyslipidemia

P. Chong, B. Yim, 2003, The Annals of pharmacotherapy.

High-density lipoprotein cholesterol and the role of statins.

P. Chong, C. Franklin, Robert Kezele, 2002, Circulation journal : official journal of the Japanese Circulation Society.

Early Experiences and Clinical Implications of Drug-Eluting Stents: Part 1

Judy W. M. Cheng, P. Chong, 2004, The Annals of pharmacotherapy.

The Low‐Density Lipoprotein Cholesterol‐Lowering Effect of Pravastatin and Factors Associated with Achieving Targeted Low‐Density Lipoprotein Levels in an African‐American Population

T. Stamos, J. Seeger, P. Chong, 2000, Pharmacotherapy.

Early Experiences and Clinical Implications of Restenosis and Drug-Eluting Stents: Part 2

Judy W. M. Cheng, P. Chong, 2004, The Annals of pharmacotherapy.

Current, New and Future Treatments in Dyslipidaemia and Atherosclerosis

P. Chong, B. Bachenheimer, 2000, Drugs.

Cost‐Efficacy Analysis of 3‐Hydroxy‐3‐Methylglutaryl Coenzyme A Reductase Inhibitors Based on Results of the STELLAR Trial: Clinical Implications for Therapeutic Selection

P. Chong, Dwight L Varner, 2005, Pharmacotherapy.

Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases.

P. Chong, 1998, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors.

P. Chong, 2002, The Annals of pharmacotherapy.

Effect of Acetaminophen on Atherosclerosis

P. Chong, Bob Kezele, Pamala J Pontikes, 2001, The Annals of pharmacotherapy.

Key Articles, Guidelines, and Consensus Papers Relative to the Treatment of Dyslipidemias—2005

Eric K. Gupta, Matthew K. Ito, K. Birtcher, 2006, Pharmacotherapy.

Relative to the Treatment of Dyslipidemias — 2005

Eric K. Gupta, Matthew K. Ito, K. Birtcher, 2006 .